This article is more than 5 years old. Information may no longer be current.
Top 5 online stories from January
Click Here to Manage Email Alerts
Endocrine Today compiled a list of the top five news reports from January.
Healio.com/Endocrinology readers were interested in commercial weight-loss diets, task force recommendation for community health workers, and much more.
Mayo Clinic Diet ties with Weight Watchers as Best Commercial Diet by U.S. News & World Report
The Mayo Clinic Diet has been named the best commercial diet and tied with Weight Watchers, according to the U.S. News & World Report 2017 best diet rankings.
“We are honored to be recognized for a weight-loss method that offers lasting results,” Donald Hensrud, MD, medical editor of the Mayo Clinic Diet and director of the Mayo Clinic Healthy Living Program, said in a press release. “With two-thirds of Americans overweight or obese, we know that managing a healthy weight can be challenging, but when people see results quickly, they feel empowered to continue on their journey to a healthier weight.” Read more.
CDC task force recommends engagement with community health workers for diabetes prevention
Interventions that utilize community health workers for diabetes prevention, typically implemented in underserved communities, can improve health and reduce health disparities for adults with diabetes, according to a recent report released by a CDC task force.
The Community Preventive Services Task Force is recommending interventions that engage community health workers for diabetes prevention to improve glycemic control and weight-related outcomes among people at increased risk for type 2 diabetes. Some evidence suggests interventions may reduce rates of progression from prediabetes to type 2 diabetes, although more research is needed, the report noted. The task force finding is based on evidence from a Community Guide systematic review of 22 studies conducted through May 2015. Read more.
CMS classifies CGM as ‘durable medical equipment’
The CMS recently announced that continuous glucose monitoring devices will be categorized as “durable medical equipment,” according to a press release from the American Association of Clinical Endocrinologists and the American College of Endocrinology.
AACE and ACE are commending the ruling after a 2014 consensus conference on glucose monitoring determined that “glucose monitoring is essential to diabetes care, particularly for reducing hypoglycemia, provided it is structured.” Read more.
FDA approves HbA1c analyzer from Roche
Roche’s cobas c 513 analyzer and HbA1c Gen. 3 assay has received clearance from the FDA, according to a company press release.
The cobas c 513 analyzer is laboratory device for measuring HbA1c that provides data for 400 patient results per hour. The analyzer features direct results, eliminating the need for manual interpretation. It also provides closed tube sampling for efficiency and safety. Read more.
FDA clearance granted for device to diagnose osteoporosis
The FDA recently granted clearance to Bone Index Ltd. for the second-generation Bindex point-of-care device model used in aiding diagnoses of osteoporosis, according to a company press release.
“The clearance process with the FDA was very fast, only 6 months. ... The technique is based on extensive clinical evidence with over 2,500 patients and the position in the current care of osteoporosis is clear,” Janne Karjalainen, PhD, chief technology officer of Bone Index, said in the release. Read more.